• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Non-compressed sustained release tablets which will float on gastric fluid are described. The tablets comprise a hydrocolloid gelling agent, a therapeutically acceptable inert oil, the selected therapeutic agent and water.
    公开号:SU1679965A3
    申请号:SU864027295
    申请日:1986-04-11
    公开日:1991-09-23
    发明作者:Болтон Санфорф；Дисай Субхаш
    申请人:Форест Лабораториз Инк. (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to the pharmaceutical and pharmaceutical industry and relates to a process for the preparation of drug tablets.
    The purpose of the invention is to increase the prolonging effect of the agent.
    Example 9 g of theophylline is mixed with 2 g of light mineral oil in a beaker and mixed. In a separate beaker, 10 ml of water is added to 0.2 g of agar, stirred with a magnetic stirrer and heated to boiling. The mixture is cooled to 70 ° C and gradually added to the theophylline mixture with vigorous stirring until an oil-in-water emulsion is formed. The warm emulsion is poured into a molding plate with a plurality of hollow cylindrical shapes, each 0.46 cm high and 1.10 cm in diameter. The compositions are allowed to cool and thicken (about 5 minutes). The tablets are removed from the mold and dried. The tablet density fluctuates slightly, however, the average is 0.70.
    This product, composition 1, has the following starting composition:
    Teofillin9 g
    Light mineral oil 2 g
    Water 10 ml
    Agar 0.2 g
    EXAMPLE 2 Example 1 is repeated to obtain the following composition 2 Theophylline9 g
    Light mineral oil3 g
    Water 10 ml
    Agar 0.2 g
    Example 3: The density of ten tablets prepared from Form 2 was measured thoroughly. It ranges from 0.6943 to 0.7483. The average density is 0.7178. The average weight of the dried tablets is 317 mg, and each tablet contains:
    Theophylline 237 mg
    Light mineral
    cl
    WITH
    Os
    sg
    Yu
    ABOUT
    About SL

    with
    oil 60 mg
    Agar ,, 5.3 mg
    Water 14.7 mg
    PRI me R 4. The dissolution of theophylline from tablets formed from compounds 1 and 2 is determined by the standard US Pharmacopoeia basket method at 50 rpm. The results are shown in the table, these values being the percent release of theophylline.
    From these values it is found that the tablets release theophylline contained in them for an extended period of time.
    Example 5: Theophylline concentration in the blood plasma of male adult volunteers is determined after they swallow a single 237 mg tablet of formulation 2. The values are as follows:
    Time, h Concentration, µg / ml
    1O
    31.7
    61.95
    122.7
    183.75
    243.2
    Prolonged action is evident from the indicated numbers.
    PRI me R 6.
    Weight,%
    Theophylline839,8
    Light mineral
    oil 210.0
    Water10 49.7
    Agar0.1 0.5
    The dry tablet has a density of 0.7 and the following release pattern, determined by the standard basket basis method at 50 rpm in a dissolved medium (pH 1.2):
    Time .h% release of theophylline
    119.1
    321.1
    541.6
    850,9
    1262.0
    PRI me R 7. The following composition is processed as described in example 1: Weight, g%
    Theophylline3.8 25.0
    Light mineral
    oil 1.2 8.0
    Water10 66.5
    Agar0.07 0.5
    Tablets have a density of 0.6 and the release of 80% of the drug after 5 hours in the medium of mean pH 1.2.
    Example Tablets are prepared from the following composition using the method described in Example 1:
    Weight,
    Theophylline633.0
    Light mineral oil211.0
    Agar0.2 1.1
    Water10 54.9
    Tablets have a height of 3.17 mm and a diameter of 11.11 mm.
    The average weight of one tablet is 231 mg and a density of 0.56.
    The release rate is determined in a medium with a pH of 1.2.
    Time h% release of theophylline
    124
    235
    342
    447
    551
    656 863
    PRI me R 9. The following composition is processed into tablets by the method of example 1:
    Weight, g. % 0
    Theophylline28 50.0
    Light mineral oil17 30.3
    Water 10 17.9
    Agar11,8
    Tablets have a density of less than 1 and float on the surface of simulated gastric juice.
    The tablet is characterized by a network of numerous air vents and channels. Due to this unique structure, the tablet has a density of less than 1 and floats on the surface of the gastric fluid.
    An example. Theophylline tablets were prepared from the following composition using carrageenan as a gel-forming agent
    Weight,%
    Theophylline6.0 32.8
    Karagenan0.3 1.6
    Light mineral oil2.0 10.9
    Water10.0 54.6
    Theophylline and mineral oil are loaded into a beaker and mixed. The water and carrageenan are stirred and heated to boiling to form a solution. The carrageenan solution is cooled to 70 ° C and the theophylline oil is gradually added to the mixture with vigorous stirring to form an oil-in-water emulsion. diameter 1.11 cm. Compositions in tablet forms are cooled to a gel state for 5 minutes. The tablets are removed from the mold and air dried for 24 hours. The tablets weigh 234 mg, have a hardness of 6.2 kg and an average density (for 10 tablets) of 0.576.
    The composition of the dried tablets was determined by extraction and analysis, which led to the following results: Weight, g%
    Theophylline173.2 74.0
    Light mineral
    oil40,5 17,3
    Caragenan9.1 3.9
    Water11.0 4.7
    Floating tablets had the following discharge pattern:
    Time, h% allocation Total allocation,%
    12525
    22146
    31662
    41072 6 1991 PrimeI. Teofillin tablets
    prepared according to the method of example 1 using carrageenan as a gel-forming agent of the following composition: Weight, g%
    Theophylline6.0 32.8
    Xragenan0.3 1.6
    Mineral
    oil2 10.9
    Water10.0 54.6
    After 24 hours of air drying, a tablet with a size of 1.11 x 0.48 cm weighs 237 mg, has a hardness of 5.2 kg and a density of 0.580.
    The dissolution test was carried out in 0.1 normal hydrochloric acid (pH 1.3) at a speed of 50 rpm and 37 ° C. Floating tablets have the following character. Exposure test:
    Time, h% allocation Total allocation,%
    14040
    23070
    31888 4593 5396
    Example 12: Theophylline tablets were prepared according to the procedure of Example 1 using carrageenan and bean cicada resin (locust bean qum) as a gel-forming agent in the following composition:
    Weight,%
    Theophylline6.033.0
    Karagenan0,10,5
    Bean gum
    cicadas0,10,5
    Mineral
    oil2.011.0
    Water 10,054,9
    After 24 hours of air drying, the tablet with a size of 1.11 x 0.48 cm weighs 224 mg, has a hardness of 5.7 kg and a density of 0.562. The dissolution test is carried out in 0.1
    normal hydrochloric acid (pH 1.3) at 50 rpm and 37 ° C. Floating tablets have the following discharge pattern:
    Time,% h% allocation Total excretion,%
    12727
    22148
    31765
    41580 5 5 787
    6794
    Example 13: Theophylline tablets were prepared according to the procedure of Example 1 using a mixture of carrageenan and bean resin 0 of cicada as a gel-forming agent of the following composition:
    Weight, mg%
    Theophylline6.0 32.8
    Caragenan 0.2 1.1
    5 Resin bean
    cicada0.1 0.5
    Mineral
    oil2 10.9
    Water1.0 54.6
    0After 24 hours air drying tablet
    1.11 xO in size, 48 cm weighed 221 mg, had a hardness of 7.9 kg and a density of 0.546.
    The dissolution test is carried out in 0.1 normal hydrochloric acid (pH 1.3) at 5–50 rpm and 37 ° C. Floating tablets exhibit the following release characteristics.
    Time, h% allocation Total allocation,%
    01.2020
    21131
    3839
    4645
    5651
    56657
    8563
    101073
    12679
    Example 14. Theophylline 0 tablets were prepared according to the procedure of Example 1 using alginic acid and bean cicada gum as a gel-forming agent of the following composition:
    Weight,%
    5 Theophylline6.0 32.8
    Alginic acid 0.2 1.1 Bean resin
    cicada0.1 0.5
    Mineral oil 2.0 10.9 Water10.0 54.6
    After 24 hours. The air-dried tablet with a size of 1.11 x 0.48 cm weighed 226 mg, had a hardness of 7.4 kg and a density of 0.554.
    The dissolution test is carried out in 0.1 normal hydrochloric acid (pH 1.3) at 50 rpm and 37 ° C.
    Floating tablets have the following discharge characteristics:
    Time, h% allocation Total allocation,%
    120,220,2
    27,727,9
    36,834,7
    44,439,1
    54,743,8
    64,147.9 8 6,254,1 10 5,559,6 12 5.064,6
    Example 15 Ampicillin floating tablets are prepared using agar as a gel-forming agent according to the following composition:
    Weight, g% Ampicillin anhydrous90, 0 32.5 Light mineral oil 16.0 5.8 Agar 3.2 1.15 Sodium citrate 8.0 2.9 Water160.0 57.7 To ampicillin preloaded in a 500 ml beaker mineral oil and mix thoroughly with glass sticks. In a separate beaker, water is heated to 90 ° C and sodium citrate is dissolved in it with stirring. Agar is added to the aqueous solution and stirred with heating until the agar is dissolved. The mixture of ampicillin oil, which was in powder form, was added in portions to the agar solution at 70 ° C and stirred with an electric stirrer until a uniform creamy suspension was obtained. The suspension is poured into a tablet mold at 48-50 ° C. The suspension is gelled after cooling for 10 minutes. Excess gel is scraped from the top of the mold, the tablets are removed from the mold and dried in air at room temperature for 24 hours.
    The average weight of 1.11 x 0.635 cm tablets is 423 mg with a density of 0.69. The hardness is 11.7 kg and the brittleness is 0.9%. The dissolution test is carried out in water at 100 rpm and 37 ° C. Floating tablets have the following release characteristics:
    Time,% h%
    0
    five
    1 2 3
    four
    five
    6
    7
    eight
    ten
    12
    14
    sixteen
    18
    17.8
    9.9
    7.0
    5.8 4.4 4.7 3.1 2.6 2.6 5.1 3.2 3.4 3.4 4.6
    General allocation,%
    17.8 27.7 34.7
    40.5 44.9 49.6 52.7 55.3 60.4 63.6 69.1 72.5 77.1
    Example 6 Ampicillin floating tablets of the following composition are prepared using agar as a gel-forming agent:
    Weight, g% Ampicillin anhydrous6, 0 32.1 Light mineral
    oil2 10.7
    Agar0.2 1.1
    Sodium citrate 0.5 2.7
    Water10.0 53.5
    Tablets are prepared according to the method of Example 6. The dissolution test for air-dried tablets is carried out in water at 50 rpm and 37 ° C. Floating tablets have the following characteristics of excretion: Time, h% excretion Total release,%
    216,916,9
    410,827,7
    610,036,7
    86,643,3
    104,948.2
    126,054,2
    PRI me R 17. Captopril tablets were prepared according to the procedure of Example 6 using agar as a gel-forming agent in accordance with the following composition:
    Weight, g. %
    Captopril7.0 35.7
    Light mineral
    . oil1.0 5.1
    J Agar0.3 1.5
    Lactose 1.0 5.1
    Calcium Gluconate 0.3 1.5
    Water10.0 51.0
    The captopril-oil mixture is added to an aqueous solution containing agar, lactose and calcium gluconate at 70 ° C and, after thorough mixing, is poured into a mold for tablets at 50 ° C. Molded gel-shaped tablets are air dried in
    for 36 hours. The size of the dried tablet is 0.95x0.32 cm and the average tablet weight is 134 mg, the hardness is 9.9 kg and the average tablet density is 0.817. The fragility test showed less than 0.84%.
    The dissolution test is carried out in accordance with the US pharmaceutical test using a centrifuge at a speed of 50 rpm at 37 ° C using a medium containing 0.1 normal hydrochloric acid and 0.001% ethylenediaminetetraacetic acid for dissolution. Floating tablets show the following discharge characteristics:
    Time,% h%
    1 2 3 4
    63.7 24.2
    7.2 4.6
    General allocation,%
    63.7
    87.9
    95.1
    99.7
    Example 18. Captopril tablets were prepared by the method of Example 6 using agar as a gel-forming agent in accordance with the following composition:
    Weight,%
    Captopril7.0 36.3
    pH 1.2 Time, h% allocated - General
    0
    five
    Light mineral oil2.0 10.4
    Agar0.3 1.5
    Water10.0 51.8
    The formed tablets are air dried for 24 hours. The size of the dried tablets is 0.95x0.32 cm and the average weight is 125 mg, the tablet hardness is 6.2 kg and the average tablet density is 0.69.
    PRI me R 19. Tablets with theophylline obtained using zgara as a gel-forming agent in accordance with the following composition:
    Weight, 9.0 g
    % 42.4
    0
    2,0 0,2 10,0
    9.4 0.9 47.2
    five
    her
    Theophylline
    Light mineral
    butter
    Agar
    Water
    Tablets were prepared according to the method of Example 1. After drying for 24 hours in air, the average density of the tablets, 1.10x0.46 cm, is 0.70.
    Floating tablets have the following discharge characteristics:
    pH7.4 you-% discharged- total you
    PRI me R 20. Tablets with theophylline obtained by the method of example 1 using agar as a gel-forming. agent in accordance with the following composition:
    Theophylline
    Light mineral
    butter
    Agar
    Water
    Weight, 9.0 g
    3.0
    0.2 10.0
    % 40.5
    13.5
    0.9
    45.0
    Molded tablets were dried on air for 24 hours. The average tablet size was 1.11x0.45 cm, average weight
    tablets were 317 mg and the average tablet density was 0.718.
    The composition of the dried tablets was as follows:
    Weight, g 237.0
    % 74.8
    Theophylline Light mineral oil60.0 18.9
    Agar5.3 1.7
    Water14.7 4.6
    Floating tablets have the following release characteristics at 50 rpm and 37 ° C in dissolution media at pH 1.2 and pH 7.4:
    The blood concentration of theophylline in an adult male volunteer was determined after swallowing one tablet containing theophylline in an amount of 237 mg:
    Time, h Concentration, mic
    programs / ml
    1O
    31.7
    61.95
    122.7
    183.75
    243.2
    Plasma concentration data show prolonged release of therapeutic agent.
    Example21. Theophylline tablets are prepared according to the method of Example 1 using agar as a gel-forming agent in accordance with the following composition:
    Weight,%
    Theophylline6.0 33.0
    Mineral
    butter. 2.0 11.0
    Agar0.2 1.1
    Water10.0 54.9
    The formed gel tablets are air-dried for 24 hours. The size of the dried tablets is 1.11x0.48 cm and the average weight of the tablet is 231 mg. The tablet hardness is 6.1 kg and the average tablet density is 0.56. .
    The dissolution test is carried out according to the centrifuge method at a speed of 50 rpm at 37 ° C in 0.1 normal hydrochloric acid with
    pH 1.3 of dissolution medium. Floating tablets have the following discharge characteristics:
    Time,% h%
    1 2 3 4 5 6 8
    24 11 7 5 4 5 7
    Total Excretion,% 24 35 42 47 51 56 63
    权利要求:
    Claims (1)
    [1]
    Floating tablets give rise to increased tablet retention time in the stomach, followed by a prolonged action of the drug for therapeutic action in the stomach and intestines. It also reduces the number of dosages required for effective therapeutic treatment. The method for producing tablets by mixing the active substance with a gelling agent, water, shaping the mixture obtained, cooling and drying, characterized in that, in order to increase the prolonging effect of the agent, theophylline or ampicillin or captocryl is mixed with the active substance mineral oil in the amount of 12–20%, carrageenan or agar in the amount of 0.5–4% is taken as the gelatinous substance, and 50–75% by weight of the tablet is used as the active substance.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1679965A3|1991-09-23|Method for manufacturing tablets
    US3279998A|1966-10-18|Method of preparing sustained release tablets
    US6077524A|2000-06-20|Gastric acid binding chewing pastilles
    SU1364226A3|1987-12-30|Method of bacampycillin acid salt microcapsulation
    RU2059409C1|1996-05-10|Method of microcapsulated composition producing
    KR950008769B1|1995-08-08|Swallowable tablet containing polycarbophil
    US3632739A|1972-01-04|Solid sustained release pharmaceutical preparation
    JPH0685688B2|1994-11-02|Chewable mineral supplement
    US4150110A|1979-04-17|Coated granules of polyacrylic alkali metal salts and method of producing same
    WO1991006281A1|1991-05-16|Gastric preparation
    KR930008956B1|1993-09-17|Process for preparing preparation of sustained release of ibuprofen
    US3078216A|1963-02-19|Prolonged release oral pharmaceutical preparations
    US6291462B1|2001-09-18|Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
    US4814178A|1989-03-21|Floating sustained release therapeutic compositions
    US5087447A|1992-02-11|Pharmaceutical preparations of high gastric acid binding capacity, delayed effect and of increased bioavailability
    WO1992004013A1|1992-03-19|Multiparticulate sustained release matrix system
    RU2041643C1|1995-08-20|Method for manufacture of feed additive for ruminants
    EP0198769A2|1986-10-22|Floating sustained release therapeutic compositions
    US5633005A|1997-05-27|Dimeticon pastilles
    US4828839A|1989-05-09|Method for making a guar flour chewable dosage unit
    JP2003518486A|2003-06-10|Controlled release pharmaceutical compositions containing tramadol hydrochloride and methods for their preparation
    US4001389A|1977-01-04|Slow release biologically active materials for feeding to ruminant animals
    Madan et al.1978|New method of preparing gelatin microcapsules of soluble pharmaceuticals
    FR2464713A1|1981-03-20|BIODEGRADABLE COMPOSITIONS WITH CONTROLLED RELEASE OF GROWTH ENHANCING AGENTS AND THEIR USE IN RUMINANTS
    US4150162A|1979-04-17|Fish feeding product and method of making the same
    同族专利:
    公开号 | 公开日
    PL149493B1|1990-02-28|
    US4814179A|1989-03-21|
    ES8802466A1|1988-07-16|
    JPS61246120A|1986-11-01|
    DK162986A|1986-10-13|
    BE904899A|1986-10-01|
    ES553900A0|1987-11-01|
    ES8800594A1|1987-11-01|
    ES557776A0|1988-07-16|
    DK162986D0|1986-04-10|
    YU58386A|1987-10-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3323922A|1965-08-09|1967-06-06|Pillsbury Co|Protective coatings|
    US3483002A|1966-11-15|1969-12-09|Kohnstamm & Co Inc H|Gelatinous coloring composition and process|
    US4126672A|1976-02-04|1978-11-21|Hoffmann-La Roche Inc.|Sustained release pharmaceutical capsules|
    US4167558A|1976-02-13|1979-09-11|Hoffmann-La Roche Inc.|Novel sustained release tablet formulations|
    US4140755A|1976-02-13|1979-02-20|Hoffmann-La Roche Inc.|Sustained release tablet formulations|
    US4089981A|1976-06-04|1978-05-16|Maxfibe Foods, Inc.|Fibrous simulated food product with gel structure|
    US4434153A|1982-03-22|1984-02-28|Alza Corporation|Drug delivery system comprising a reservoir containing a plurality of tiny pills|
    US4451260A|1982-03-26|1984-05-29|Minnesota Mining And Manufacturing Company|Sustained release oral medicinal delivery device|
    FR2537844B1|1982-12-17|1985-08-23|Roquette Freres|LOZENGE-LIKE PELLETS BASED ON SORBITOL OR CRYSTALLIZED FRUCTOSE AND THEIR MANUFACTURING METHOD|
    JPS6124516A|1984-07-12|1986-02-03|Fujisawa Pharmaceut Co Ltd|Long active tablet|
    JPH0157086B2|1984-08-03|1989-12-04|Nippon Shinyaku Co Ltd|
    GB8507779D0|1985-03-26|1985-05-01|Fujisawa Pharmaceutical Co|Drug carrier|DE3803482A1|1988-02-05|1989-08-17|Lohmann Therapie Syst Lts|FLOATING ORAL THERAPEUTIC SYSTEM|
    US5158777A|1990-02-16|1992-10-27|E. R. Squibb & Sons, Inc.|Captopril formulation providing increased duration of activity|
    US5198229A|1991-06-05|1993-03-30|Alza Corporation|Self-retaining gastrointestinal delivery device|
    US5169638A|1991-10-23|1992-12-08|E. R. Squibb & Sons, Inc.|Buoyant controlled release powder formulation|
    IN186245B|1997-09-19|2001-07-14|Ranbaxy Lab Ltd|
    US6159491A|1999-02-12|2000-12-12|Biovector Technologies, Inc.|Prolonged release bioadhesive vaginal gel dosage form|
    US20060128657A1|2003-08-04|2006-06-15|Jallal Messadek|Selected betaines and their uses|
    DE10014588A1|2000-03-27|2001-10-04|Basf Ag|Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone|
    US6955821B2|2000-04-28|2005-10-18|Adams Laboratories, Inc.|Sustained release formulations of guaifenesin and additional drug ingredients|
    US7985420B2|2000-04-28|2011-07-26|Reckitt Benckiser Inc.|Sustained release of guaifenesin combination drugs|
    US8012504B2|2000-04-28|2011-09-06|Reckitt Benckiser Inc.|Sustained release of guaifenesin combination drugs|
    US7838032B2|2000-04-28|2010-11-23|Reckitt Benckiser Inc.|Sustained release of guaifenesin|
    EP1245227A1|2001-03-31|2002-10-02|Jagotec Ag|A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same|
    AU2008255254B2|2001-03-31|2010-12-09|Jagotec Ag|A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substance and respective processes of producing same and a cup-shaped envelope of same|
    WO2003037301A2|2001-10-29|2003-05-08|King Pharmaceuticals Research And Development, Inc|Oral dosage forms for improving the bioavailability of therapeutic agents|
    AU2002302890A1|2002-02-04|2003-12-02|Ranbaxy Laboratories Limited|Hydrodynamically balancing oral drug delivery system with biphasic release|
    WO2003089506A1|2002-04-22|2003-10-30|Purdue Research Foundation|Hydrogels having enhanced elasticity and mechanical strength properties|
    US20040109889A1|2002-12-04|2004-06-10|Bunick Frank J.|Surface treatment composition for soft substrates|
    NZ523946A|2003-01-31|2004-06-25|Carl Ernest Alexander|Portable hygiene compositions comprising a semi-solid gel and active ingredients in bead form for use in personal oral, dental or skin care|
    WO2004091601A1|2003-04-17|2004-10-28|Jallal Messadek|Floating oral formulations for controlled release of betaine|
    BE1015608A6|2003-07-15|2005-06-07|Messadek Jallal|TREATMENT arteritis.|
    BE1016128A6|2004-07-22|2006-03-07|Messadek Jallal|Combination therapy|
    WO2006050581A2|2004-11-10|2006-05-18|Jallal Messadek|Betaine as agent against arthropod - or mosquito -borne diseases|
    WO2006086856A1|2005-02-15|2006-08-24|Messadek, Jallal|Combination therapeutic compositions and method of use|
    AT540690T|2005-04-27|2012-01-15|Jallal Messadek|INSULIN COMBINATION|
    US20070178155A1|2006-01-31|2007-08-02|Jiang David Yihai|Preparation for gastric buoyant sustained drug release dosage form|
    AT505225A1|2007-04-26|2008-11-15|Sanochemia Pharmazeutika Ag|Tolperisone and their pharmaceutical acceptable salts and hydrates production for use as active substance in pharmaceutical formulation for drugs, for treatment and therapy of Alzheimer's disease, involves converting methylpropiophenone|
    WO2009065193A1|2007-11-21|2009-05-28|Jallal Messadek|Treatment of aspirin resistance with betaine and/or betaine enriched molasses|
    EP2133071A1|2008-06-09|2009-12-16|Université de la Méditerranée|Process for making gastroretentive dosage forms|
    US20100249423A1|2009-03-09|2010-09-30|Sanochemia Pharmazeutika Ag|Tolperisone controlled release tablet|
    EP2444064A1|2010-10-22|2012-04-25|Meliatys|Process for making multiparticulate gastroretentive dosage forms|
    AU2013235266B2|2012-03-20|2017-10-19|Particle Dynamics International, Llc|Gelling agent-based dosage form|
    ES2536836T3|2012-10-12|2015-05-29|Omya International Ag|Formulation of gastro-retentive medication and release systems and their method of preparation using calcium carbonate transformed into functional|
    PL235144B1|2014-06-03|2020-06-01|Univ Medyczny Im Piastow Slaskich We Wroclawiu|Method for manufacturing flotation tablet with prolonged action of therapeutic substances with the stomach mucous membrane and the pharmaceutical composition|
    EP3034070A1|2014-12-18|2016-06-22|Omya International AG|Method for the production of a pharmaceutical delivery system|
    EP3069713A1|2015-03-20|2016-09-21|Omya International AG|Dispersible dosage form|
    EP3269361A1|2016-07-14|2018-01-17|Omya International AG|Dosage form|
    WO2020230089A1|2019-05-14|2020-11-19|Clexio Biosciences Ltd.|Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US72283285A| true| 1985-04-12|1985-04-12|
    [返回顶部]